We are developing generative AI to support decision-making for healthcare professionals and the general public. Specifically, Cubec functions as a learning support tool that answers questions arising in physicians’ daily practice, and it generates revenue by providing pharmaceutical companies with high-precision data on physician needs. We are planning a phased business rollout, with the ultimate goal of implementing as a Software as a Medical Device (SaMD) that supports physicians’ clinical decision-making.
医師向け臨床ナレッジAI「Cubec」を開発する株式会社Cubec（本社：大阪府吹田市、代表取締役CEO：奥井 伸輔）は、2026年2月に「Cubec」のシステムアップデートを実施し、「高速・推論・論文」の3モードを搭載しま...
[画像1: https://prtimes.jp/i/124652/7/resize/d124652-7-ba24ae8e703572f504f9-4.png ] 臨床ナレッジAI「Cubec」を開発する株式会社Cubec（本社：大阪府吹田市、代表取締役CEO：奥井 伸輔）は、2025年12月4日に...
[画像: https://prtimes.jp/i/124652/6/resize/d124652-6-ae4e38298d8a616781ef-0.png ] 臨床ナレッジAI「Cubec」を開発する株式会社Cubec（本社：大阪府吹田市、代表取締役CEO：奥井 伸輔）は、京都キャピタルパ...
[画像1: https://prtimes.jp/i/124652/4/resize/d124652-4-50cff9910d0a18b51186-1.png ] 株式会社Cubec（本社：兵庫県神戸市東灘区、代表取締役CEO：奥井 伸輔）は、医師が抱える疑問に対し、信頼性の高い情報を...
[画像: https://prtimes.jp/i/124652/3/resize/d124652-3-2c0fd013495593c0dc10-0.jpg ] 写真提供：国立研究開発法人国立循環器病研究センター株式会社Cubec（以下、Cubec 本社：兵庫県神戸市東灘区、代表取締役...
Microsoft for Startups とは Microsoft for Startupsは、マイクロソフト社が世界140カ国以上にグローバル展開しているスタートアップ支援プログラムです。 革新的な技術やサービスを開発・提供をしているスタ...
[画像1: https://prtimes.jp/i/124652/1/resize/d124652-1-9de75484260b06329c8c-3.png ] 心不全患者が激増する「心不全パンデミック」 心不全は、心臓が全身に血液や酸素を送る「ポンプの機能」が働かなくな...
Cells in living organisms function in an orderly manner by cooperating with surrounding cells while interacting with extracellular proteins. However, in cell culture systems, extracellular proteins are largely absent, making it difficult for cells to function properly and often causing them to exhibit physiological activities that differ from those observed in vivo. Our company conducts research on extracellular matrix proteins located outside the cell, and by applying the findings from this research to cell culture technologies, we aim to contribute to the advancement of regenerative medicine and the realization of alternatives to animal experimentation.
A startup developing mass-producible platelet preparations using technology to generate platelets from human iPS cells. It aims to provide stable supplies to medical settings in developed and developing countries facing blood donation shortages, thereby supporting transfusion medicine.
Development of technology for assessing micronutrient intake using hair and provision of analysis services.
NUProtein develops next-generation protein and bioactive compound production technologies using genetically engineered rice. By cultivating high-expression rice and extracting target components directly from the grain, the company achieves exceptionally low-cost and stable production compared with conventional methods. NUProtein is also recognized as one of the world’s five industrial players in cell-free protein synthesis and gene-related patents. Through low-cost growth factors and other functional proteins, the company is building a new supply chain for the cultivated meat and broader food-tech sectors.
